Document:

<PAGE>

                                                                 Exhibit 10.1(k)

                                LICENSE AGREEMENT

               This License Agreement, to be effective as of the 1st day of
February, 1993 (hereinafter called "Agreement Date"), is by and between Baylor
College of Medicine (hereinafter called "BAYLOR"), a Texas nonprofit corporation
having its principal place of business at One Baylor Plaza, Houston, TX 77030,
and Genica Pharmaceuticals Corporation, (hereinafter called "GENICA"), a
corporation organized under the laws of the Commonwealth of Massachusetts, and
having its principal place of business at Two Biotech Park, 373 Plantation
Street, Worcester, MA 01605.

               WITNESSETH:

               WHEREAS, BAYLOR is the owner of the Subject Technology as defined
below; and

               WHEREAS, BAYLOR is desirous of granting to GENICA a
royalty-bearing, worldwide license to the Subject Technology, which shall be
exclusive, except as set forth in Paragraphs 2.2 and 2.3, on the terms set forth
herein; and

               WHEREAS, GENICA desires to obtain said exclusive license under
the Subject Technology.

               NOW, THEREFORE, for and in consideration of the premises and
other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto expressly agree as follows:

1.       DEFINITIONS AS USED HEREIN
         --------------------------

               1.1 The term "Subject Technology" shall mean all technology,
biological materials, trade secrets, kits, compounds, know-how, methods,
documents, materials, tests, probes and all confidential information related to
the diagnosis of Charcot-Marie Tooth Disease which was developed by Dr. James R.
Lupski, Dr. Pragna Patel, Mr. Montes de Oca-Luna and Ms. Saucedo Cardenas in
laboratories at BAYLOR. The Subject Technology shall also include United States
Patent Application Serial No. 07/711,615 filed June 6, 1991, entitled "Molecular
Diagnosis of Charcot-Marie Tooth Disease," together with all valid patents or
patent applications, reexaminations, reissues, renewals, extensions, divisions
and any foreign counterparts thereof (the "Licensed Patents"). The
continuation-in-part application of United States Serial No. 07/711,615 is
specifically excluded from the term "Subject Technology."

               1.2 The term "Field" shall mean use of the Subject Technology
solely for commercial diagnostic purposes. The research market is specifically
excluded from the term "Field."

               1.3 The term "Licensed Product(s)" shall mean products or
services which are derived from, incorporate or utilize, in whole or in part,
the Subject Technology.

* Material omitted and filed separately with the Securities and Exchange
Commission pursuant to request for confidential treatment under Rule 406.

<PAGE>

               1.4 The term "Combination Product" shall mean a diagnostic
product developed and sold by GENICA or its Affiliates that is comprised in part
of Licensed Product(s) and one or more other patented products or parts. The Net
Sales for the purposes of determining royalties on Licensed Products shall be
calculated by multiplying the Net Sales of the Combination Product by the
fraction A/A+B, where A is the invoice price for the Licensed Products and B is
the invoice price for the patented products or parts of the Combination Product
if sold separately. If the Licensed Products or other patented products or parts
of the Combination Product are not sold separately, the Net Sales for
determining royalties shall be calculated by multiplying the Net Sales of the
Combination Product by the fraction C/C+D, where C is the cost for producing the
Licensed Products and D is the cost for producing the other patented products or
parts in the Combination Product. If GENICA finds it necessary to license other
patents to enabling technology or other genes for CMT for which it must pay
royalties, then the royalty rate paid to BAYLOR as stated in Paragraph 4.2 shall
be reduced by no more than [ ]%*.

               1.5 The term "Net Sales" shall mean the gross amount of monies or
monetary equivalent of other consideration received from unrelated third parties
by GENICA or its Affiliates for Licensed Products by sale or other mode of
transfer, less all trade, quantity and cash discounts actually allowed, credits,
and allowances actually granted on account of rejections, returns or billing
errors, duties, any separately identified charges for transportation and
insurance, taxes and other governmental charges actually paid. The term "Net
Sales" in the case of non-cash sales, shall mean all equivalent consideration
received by GENICA for Licensed Products. If the Parties fail to reach agreement
on the fair value of equivalent consideration received for non-cash sales, the
Parties agree that an independent third party mutually acceptable to both
Parties shall be appointed to determine the fair value of equivalent
consideration received.

               1.6 The term "Sublicensing Revenues" shall mean the amount
actually paid to GENICA by Sublicensees arising from the sublicensing of the
right to make, have made, use or sell Licensed Products. Sublicensing Revenues
shall include license fees, royalties and any other payment in respect to
Licensed Products, but shall not include any payments tied to the provision of
goods and services by GENICA to such Sublicensee to compensate GENICA for the
provision of such goods and services.

               1.7 The term "Affiliates" shall mean any corporation,
partnership, joint venture or other entity of which the common stock or other
equity ownership thereof is [           ]%* or more owned by GENICA.

               1.8 The term "the Parties" shall mean GENICA and BAYLOR.

2.       GRANT OF LICENSE
         ----------------

               2.1 BAYLOR hereby grants to GENICA an exclusive, worldwide
license with the right to grant sublicenses hereunder, under the Subject
Technology to make, have made, use, and sell Licensed Products in the Field.

                                       -2-

<PAGE>

               2.2 BAYLOR shall at all times retain the right to use the Subject
Technology for research and commercial purposes in diagnostic and other
laboratories which are owned and operated by and are located at BAYLOR or any of
its affiliated health care entities and which are staffed in whole or in part by
full-time BAYLOR faculty members. James R. Lupski and Pragna I. Patel shall at
all times retain the right to use the Subject Technology solely for research,
non-commercial purposes. In addition, BAYLOR reserves the right to: (i) provide
to academic institutions solely for research, non-commercial purposes, the
Subject Technology and (ii) grant licenses to the Subject Technology solely for
research, non-commercial purposes to other third parties. BAYLOR agrees that
before it (i) provides the Subject Technology for research purposes to other
academic institutions, or (ii) licenses the Subject Technology for research
purposes to other third parties, it will require that these institutions or
third parties sign an agreement whereby they consent not to sell or offer to
sell products or services for the clinical diagnosis of CMT covered by the
Subject Technology nor will they provide diagnostic results to others including
medical professionals where such results might be used in the screening or
clinical management of human patients.

               2.3 The exclusive license granted to GENICA hereunder shall also
be subject to and nonexclusive with respect to, any nonexclusive license which
BAYLOR is required by law to grant to the United States government or to a
foreign state pursuant to any existent or future treaty with the United States.

               2.4 Upon written request by James R. Lupski or Pragna I. Patel,
GENICA agrees to undertake reasonable efforts to provide samples of patient
serum or other fluids or tissues to the individual laboratories of James R.
Lupski and Pragna I. Patel for research purposes in connection with the Subject
Technology.

3.       BEST EFFORTS
         ------------

               GENICA shall use Best Efforts to effect introduction of Licensed
Products into the commercial market as soon as practicable, consistent with
sound and reasonable business practices and judgment. For purposes of this
paragraph, "Best Efforts" shall include, but not be limited to, meeting the
following milestones of introducing the Licensed Products to the market:

         *      GENICA shall (i) train its salesforce to sell CMT tests, (ii)
                mail product introduction information to neurologists within
                thirty (30) days of launch, and (iii) have an advertisement in a
                key journal (i.e. American Journal of Human Genetics,
                Neurobiology, Annals of Neurology and American Journal of
                Medical Genetics) or other promotional mechanisms in place at
                GENICA's sole discretion, within nine (9) months of the launch
                date, or such reasonable time as makes marketing sense.

         *      GENICA must exhibit at a major conference (i.e. American Society
                of Human Genetics and/or American Neurology Association or
                similar body) within one year of the Agreement Date.

                                       -3-

<PAGE>

         *      GENICA shall train technicians to the acceptance of Drs. Lupski
                and Patel.

         *      GENICA shall have technicians at GENICA with the appropriate
                skill to sufficiently perform any of the methods (including
                fluorescent in-situ hybridization, southern blot analysis, PCR
                and pulsed-field gel electrophoresis) that are necessary to meet
                market needs to diagnose CMT within sixty (60) days of the first
                determination of a market need.

         *      BAYLOR shall (i) provide reasonable amounts of the tangible
                materials of the Subject Technology including all necessary
                probes for the diagnosis of CMT to GENICA as soon possible after
                the Agreement Date, (ii) participate in a blind pool study with
                GENICA and (iii) reasonably train a technician of GENICA in
                laboratories of James R. Lupski and/or Pragna I. Patel at
                BAYLOR.

         *      GENICA shall launch a commercial product within six months of
                the date of receipt of tangible materials of the Subject
                Technology.

4.       PAYMENT
         -------

               4.1 As partial consideration for the rights conveyed by BAYLOR
under this License Agreement, GENICA agrees to pay BAYLOR a license fee of $[
]*. The payment shall be as follows: (i) $[         ]* contemporaneously upon
the execution of the License Agreement; (ii) $[         ]* within six months of
the initial sale of a Licensed Product under the License Agreement and (iii) the
remaining $[         ] within twelve (12) months of the initial sale of product.

               4.2 In addition to the foregoing license execution fee, GENICA
agrees to pay and shall pay to BAYLOR a running royalty of [         ]%* of Net
Sales of all Licensed Products sold by GENICA or its Affiliates. Such running
royalties shall be payable as provided in Paragraph 4.5. GENICA may offset
against any royalty payment due from a particular foreign country the patent
costs from such particular foreign country.

               4.3 In addition to the foregoing fees and running royalties,
GENICA agrees to pay to BAYLOR the following annual minimum royalty payments,
with the start of Year One being defined as the date of the initial sale of
Licensed Products under the License Agreement:

         Year One                                 $[      ]
         Year Two                                 $[      ]
         Year Three                               $[      ]
         Year Four                                $[      ]
         Year Five                                $[      ]

The first payment shall be due within thirty (30) days of the anniversary of
Year One. Each such subsequent payment shall be due within thirty (30) days of
each of the second, third,

                                       -4-

<PAGE>

fourth, and fifth anniversaries of Year One. Each such annual minimum royalty
payment shall be creditable against royalties due that year payable under
Paragraph 4.2.

               4.4 For sublicenses granted to the Subject Technology, GENICA
shall pay BAYLOR [         ]%* of the Sublicensing Revenue received by GENICA
during the first year of the License Agreement, [         ]%* received during
the second year of the License Agreement, [         ]%* received during the
third year of the License Agreement, [         ]%* received during the fourth
and continuing years of the License Agreement.

               4.5 If GENICA fails to pay when due all running royalties payable
under Paragraphs 4.2 and 4.4 and each annual minimum royalty payable under
Paragraph 4.3, BAYLOR may, at its sole option, convert this license to a
non-exclusive one, in which event, the royalty rate in Paragraph 4.2 shall be
reduced to [         ]%* and the annual minimum royalties in Paragraph 4.3 shall
be reduced by [         ]%*. The failure of BAYLOR to exercise such right shall
not be deemed to be a waiver of such right, nor shall such failure preclude
BAYLOR from exercising or enforcing said right upon any subsequent failure by
GENICA.

               4.6 Payment of the royalties specified in Paragraph 4.2 shall be
made by GENICA to BAYLOR within sixty (60) days after March 31, June 30,
September 30 and December 31 of each year during the term of this License
Agreement covering the quantity of Licensed Products sold by GENICA or its
Affiliates during the preceding calendar quarter. The last such payment shall be
made within sixty (60) days after termination of this License Agreement.

               4.7 All payments due hereunder are expressed in and shall be paid
by check payable in United States of America currency, without deduction of
exchange, collection or other charges, except as defined in Section 1.5, to
BAYLOR, or to the account of BAYLOR at such other bank as BAYLOR may from time
to time designate in writing.

               4.8 In the event that any payment due hereunder is not made when
due, the payment shall accrue interest beginning on the tenth day following the
due day thereof, calculated at the annual rate of the sum of (a) [         ]%*
plus (b) [         ]* on the date said payment is due, the interest being
[         ]*, provided, however, that in no event shall said annual interest
rate exceed [         ]*. Each such royalty payment when made shall be
accompanied by all interest so accrued. Said interest and the payment and
acceptance thereof shall not negate or waive the right of BAYLOR to seek any
other remedy, legal or equitable, to which it may be entitled because of the
delinquency of any payment.

5.       RECORDS, REPORTS AND INSPECTION
         -------------------------------

               5.1 Within sixty (60) days after the expiration of each calendar
quarter that begins or ends during the term of this License Agreement, GENICA
shall furnish BAYLOR

                                       -5-

<PAGE>

with a written statement of Net Sales of Licensed Products during such calendar
quarter. Such written statements shall be duly signed by an authorized signatory
of GENICA on behalf of GENICA and its Affiliates and shall show the Net Sales of
Licensed Products by GENICA and its Affiliates during such calendar quarter and
the amount of royalties payable under this License Agreement based thereon. Each
such report shall be accompanied by payment of the royalties shown to be due
thereby.

               5.2 GENICA shall maintain or cause to be maintained a true and
correct set of records pertaining to the Net Sales of Licensed Products and its
performance and the performance of its Affiliates under this License Agreement.
During the term of this License Agreement and for a period of two (2) years
thereafter, GENICA agrees to permit an independent public accountant selected
and paid by BAYLOR and reasonably acceptable to GENICA to have access during
ordinary business hours to such records as are maintained by GENICA or its
Affiliates as may be necessary, in the opinion of such auditor, to determine the
correctness of any report and/or payment made under this License Agreement. If
the event that the audit reveals an underpayment of royalty by more than
[         ]%*, the cost of the audit shall be paid by GENICA. If the
underpayment is less than [         ]%* but more than [         ]%*, GENICA and
BAYLOR shall each pay [         ]%* of the cost of the independent audit. Such
accountant shall maintain in confidence, and shall not disclose to BAYLOR, any
information directly relating to the correctness of such reports and payments.

6.       PATENTS AND INFRINGEMENT
         ------------------------

               6.1 BAYLOR shall continue, at its expense, the efforts commenced
prior to the Agreement Date to obtain a United States patent on the Licensed
Patents. GENICA shall be responsible for all of the expenses incurred after the
Agreement Date for the preparation, filing, prosecution and maintenance of
foreign patent applications and resulting foreign patents. The Parties shall
utilize patent attorneys or agents of BAYLOR's choice for the filing,
prosecution and issuance of the United States and all foreign patent
applications on the Licensed Patents. GENICA expressly authorizes and directs
BAYLOR to instruct such counsel to invoice GENICA directly for all of the
expenses and fees related to all foreign filings. GENICA shall have reasonable
input in deciding which foreign filings will be made. Should GENICA refuse to
pay for certain foreign filings, then BAYLOR may do so at its own expense,
retaining license and patent rights secured for such filings. BAYLOR shall
instruct its counsel to copy GENICA on all correspondence related to the
Licensed Patents. BAYLOR and its faculty members shall cooperate fully in the
preparation, filing and prosecution of all United States and foreign patent
applications filed pursuant to this paragraph.

               6.2 If it is believed in good faith that the Licensed Patents are
infringed by a third party, the party to this License Agreement first having
knowledge of such infringement shall promptly notify the other in writing, which
notice shall set forth the facts of such infringement in reasonable detail.
GENICA shall have the right, but not the obligation, to institute and prosecute
at its own expense an action or proceeding against any such infringement of the
Licensed Patent. If GENICA fails to bring such action or proceedings within a
period of three (3) months after receiving written notice or otherwise having
knowledge of such in-

                                       -6-

<PAGE>

fringement, then BAYLOR shall have the right, but not the obligation, to
institute or prosecute at its own expense an action or proceeding against any
infringement of the Licensed Patents. Any recovery of damages and costs in such
suits shall be apportioned as follows: the party bringing suit shall first
recover an amount equal to two times the costs and expenses incurred by such
party directly related to the initiation and full prosecution of such action and
the remainder shall be divided equally between BAYLOR and GENICA.

7.       AFFILIATES AND SUBLICENSEES
         ---------------------------

               GENICA shall be responsible for its Affiliates and sublicensees
and shall not grant any rights which are inconsistent with the rights and
obligations of GENICA hereunder. Any act or omission of an Affiliate or
sublicensee which would be a breach of this License Agreement if performed by
GENICA shall be deemed to be a breach by GENICA of this License Agreement. Each
sublicense agreement granted by GENICA to its Affiliates or sublicensees shall
include an audit right by BAYLOR of the same scope as provided by Paragraph 5.2
hereof with respect to GENICA. No such sublicense agreement shall contain any
provision which would cause it to extend beyond the term of this License
Agreement. GENICA shall give BAYLOR prompt notification of the identity and
address of each Affiliate and sublicensee with whom it concludes a sublicense
agreement and shall supply BAYLOR with a copy of each sublicense agreement.

8.       TERMINATION
         -----------

               8.1 Unless earlier terminated as hereinafter provided, this
License Agreement shall extend for the life of the last to expire Licensed
Patent or if no Licensed Patent issues, five (5) years from the Agreement Date.
After such termination, GENICA shall have a perpetual, royalty-free license to
the Subject Technology except for payment of previously accrued and unpaid
royalties due pursuant to Paragraph 4.2 hereof.

               8.2 In the event of default or failure by either party to perform
any of the terms, covenants or provisions of this License Agreement, the
nonperforming party shall have ninety (90) days after the giving of written
notice of such default by the other party to correct such default. If such
default is not corrected within the said ninety (90) day period or after BAYLOR,
at its sole discretion, accepts a suitable workplan from GENICA after notice as
aforesaid, the performing party shall have the right, at its option, to cancel
and terminate this License Agreement. Either Party shall have the right, at its
option, to cancel and terminate this License Agreement in the event that the
other Party shall (i) become involved in its insolvency, dissolution, bankruptcy
or receivership proceedings affecting the operation of its business or (ii) make
an assignment of all or substantially all its assets for the benefit of
creditors or in the event that (iii) a receiver or trustee is appointed for such
other Party and such Party shall, after the expiration of ninety (90) days
following any of the events enumerated above, have been unable to secure a
dismissal, stay or other suspension of such proceedings. In the event of
termination of this License Agreement, except pursuant to Paragraph 8.1, all
rights to the Subject Technology licensed by BAYLOR to GENICA hereunder shall
revert to BAYLOR.

                                       -7-

<PAGE>

               8.3 GENICA may terminate this License Agreement at any time upon
ninety (90) days written notice to BAYLOR. From and after the effective date of
such termination, GENICA shall cease using the Subject Technology and GENICA's
obligation to pay running royalties and annual minimum royalties hereunder shall
cease, except as to royalty payments which have accrued up to the effective date
of such termination. GENICA shall not, however, be entitled to receive a refund
of any sums paid to BAYLOR hereunder.

               8.4 At the date of any termination pursuant to Paragraph 8.2
hereof for breach by GENICA, or pursuant to Paragraph 8.3 hereof, GENICA shall
return all tangible materials of the Subject Technology to BAYLOR.

               8.5 No termination of this License Agreement shall constitute a
termination or a waiver of any rights of either Party accruing at or prior to
the time of such termination. The obligations of Paragraphs 5 and 12 shall
survive termination of this License Agreement.

9.       ASSIGNABILITY
         -------------

               This License Agreement shall be binding upon and shall inure to
the benefit of BAYLOR and its assigns and successors in interest, and shall be
binding upon and shall inure to the benefit of GENICA and its Affiliates who are
sublicensees and the successor to its entire business to which this License
Agreement relates, but shall not otherwise be assignable or assigned by either
Party without prior written approval by the other Party, which approval shall
not be unreasonably withheld.

10.      LAW
         ---

               This License Agreement shall be construed according to the Laws
of the State of Texas, United States of America; provided, however, that any
patent question or controversy shall be resolved in the courts having
jurisdiction over the patent or patents in question and in accordance with the
laws applicable to such patent or patents.

11.      ADDRESSES
         ---------

               For the purpose of reports and notices herein set forth, the
addresses set forth in the introductory paragraph of this License Agreement
shall be used unless changed by written notification by one Party to the other
Party.

12.      ADDITIONAL PROVISIONS
         ---------------------

               12.1 Use of BAYLOR Name. GENICA agrees that it may not use in any
                    ------------------
way the name of "BAYLOR" or any logotypes or symbols associated with BAYLOR or
the names of any researchers at BAYLOR without the prior written consent of
BAYLOR, which consent shall not be unreasonably withheld.

               12.2 Confidentiality. GENICA agrees to use reasonable efforts
                    ---------------
(which shall be at least as great as the efforts it uses to maintain the
confidentiality of its own confidential

                                       -8-

<PAGE>

information) to maintain the Subject Technology in confidence, and to use the
same only in accordance with this License Agreement. Such obligation of
confidentiality shall not apply to information which GENICA can demonstrate: (i)
was at the time of disclosure in the public domain; (ii) has come into the
public domain after disclosure through no fault of GENICA or its Affiliates;
(iii) was known to GENICA or its Affiliates prior to disclosure thereof by
BAYLOR or (iv) was lawfully disclosed to GENICA without obligation of confidence
by a third party which was not under an obligation of confidence to BAYLOR with
respect thereto. The foregoing obligations of confidentiality shall survive
termination of this License Agreement.

               12.3 Indemnity. Each Party shall notify the other of any claim,
                    ---------
lawsuit or other proceeding related to the Licensed Products. Subject to the
following sentence, GENICA agrees that it will defend, indemnify and hold
harmless BAYLOR and its faculty members, researchers, employees, officers,
trustees, Dr. James R. Lupski and agents and each of them (the "Indemnified
Parties") from and against any and all claims, causes of action, lawsuits or
other proceedings filed or otherwise instituted against the Indemnified Parties
related directly or indirectly to or arising out of the design, manufacture,
sale, or use of the Licensed Products or any other embodiment of the Subject
Technology by GENICA or its Affiliates except such claims, causes of action,
lawsuits, other proceedings and the costs (including attorney's fees) related
thereto which result in whole or in part from the gross negligence or
intentional misconduct of any of the Indemnified Parties. Notwithstanding any
provisions herein to the contrary, BAYLOR shall indemnify GENICA for any claims
for injuries to persons or damages which occur on BAYLOR premises or premises
under the exclusive control of BAYLOR. GENICA will also assume responsibility
for all costs and expenses related to such claims and lawsuits for which it is
obligated to indemnify the Indemnified Parties pursuant to this Paragraph 12.3,
including, but not limited to, the payment of all attorneys' fees and costs of
litigation or other defense.

               12.4 Insurance. GENICA and each of its Affiliates and
                    ---------
sublicensees as applicable, shall, for so long as GENICA, its Affiliates or
sublicensees manufacture, sell, or use any Licensed Products, maintain in full
force and effect policies of (i) worker's compensation and/or employer's
liability insurance (with Broad Form General Liability and Service Liability
endorsements) with limits of not less than $[ ] per person and $[ ] per
occurrence with no annual aggregate or such coverage as is deemed suitable by
the insurance agency and GENICA's Board of Directors. Such coverage(s) shall be
purchased from a carrier or carriers deemed acceptable to BAYLOR. Upon request
by BAYLOR, GENICA shall provide certificate(s) evidencing the coverage(s)
maintained which shall also specify that GENICA make best efforts to give BAYLOR
no less than thirty (30) days prior written notice of any change in or
cancellation of such coverage(s).

               12.5 BAYLOR's Disclaimers. Neither BAYLOR nor any of its faculty
                    --------------------
members, researchers, trustees, officers, employees, Dr. James R. Lupski or
agents assume any responsibility for the manufacture, service specifications, or
use of the Licensed Products which are manufactured by or for or sold by GENICA,
its Affiliates or its sublicensees. All warranties in connection with the
Licensed Products shall be made by GENICA (or the par-

                                       -9-

<PAGE>

ticular GENICA Affiliate or sublicensee that is involved) as the manufacturer or
seller thereof and none of such warranties shall directly or by implication in
any way obligate BAYLOR or any of its faculty members, researchers, trustees,
officers, employees, Dr. James R. Lupski or agents.

               12.6 Disclaimer of Warranty. BAYLOR makes no warranties or
                    -----------------------------------------------------
representations, expressed or implied, including, but not limited to, warranties
--------------------------------------------------------------------------------
of fitness or merchantability, regarding Licensed Products.
----------------------------------------------------------

               12.7 The failure of either Party to enforce at any time any of
the provisions of this License Agreement, or any rights in respect thereto, or
to exercise any election herein provided, shall in no way be considered to be a
waiver of such provisions, rights, or elections, or in any way to affect the
validity of this License Agreement. Exercise by either Party of any of its
rights herein or any or its elections under the terms and covenants herein shall
not preclude either Party from exercising the same or any other rights in this
License Agreement irrespective of any previous action or proceeding taken by
either Party hereunder.

               12.8 If any provision of this License Agreement is judicially or
in an arbitration proceeding determined to be void or unenforceable, such
provision shall be deemed to be severable from the other provisions of this
License Agreement which shall remain in full force and effect. Either Party may
request that a provision otherwise void or unenforceable be reformed so as to be
valid and enforceable to the maximum extent permitted by law.

               12.9 No liability hereunder shall result to a Party by reason of
delay in performance caused by force majeure, that is circumstances beyond the
reasonable control of the party, including, without limitation, acts of God,
fire, flood, war, civil unrest, labor unrest, or shortage of or inability to
obtain material as equipment.

               12.10 The terms and conditions herein constitute the entire
agreement between the Parties and shall supersede all previous agreements,
either oral or written, between the Parties hereto with respect to the subject
matter hereof. No agreement of understanding bearing on this License Agreement
shall be binding upon either Party hereto unless it shall be in writing and
signed by the duly authorized officer or representative of each of the Parties
and shall expressly refer to this License Agreement.

                  Executed this 1st day of February, 1993, to be effective as of
the day and year first above written.
<TABLE>
<CAPTION>
GENICA PHARMACEUTICALS                          BAYLOR COLLEGE OF MEDICINE
  CORPORATION
<S>                                             <C>
         /s/ Robert E. Flaherty                           /s/ Charles R. Richardson
         -------------------------------                  -------------------------
Name:    Robert E. Flaherty                     Name:     Charles R. Richardson
Title:   President and CEO                      Title:    Vice President for Finance and
</TABLE>
                                                          Administration

                                       -10-

<PAGE>

                      FIRST AMENDMENT TO LICENSE AGREEMENT

                  This First Amendment ("the First Amendment") to the License
Agreement, to be effective as of the first day of August, 1993, is by and
between Baylor College of Medicine (hereinafter "BAYLOR"), a Texas non-profit
corporation having its principal place of business at One Baylor Plaza, Houston,
Texas 77030, and Genica Pharmaceuticals Corporation (hereinafter "GENICA"), a
corporation organized under the laws of the Commonwealth of Massachusetts and
having a place of business at Two Biotech Park, 373 Plantation Street,
Worcester, MA 01605.

                  WHEREAS, BAYLOR and GENICA have entered into that certain
License Agreement effective the first day of February, 1993 (hereinafter
referred to as the "License Agreement") under which GENICA has obtained from
BAYLOR and BAYLOR has granted to GENICA a certain exclusive license to the
"Subject Technology" as defined in said License Agreement; and

                  WHEREAS, BAYLOR and GENICA desire to amend and modify certain
provisions of the License Agreement as provided herein,

                  NOW, THEREFORE, in consideration of the mutual provisions and
covenants contained herein, BAYLOR and GENICA hereby agree as follows:

         1.       The terms as defined in the License Agreement shall have the
                  same meanings in this First Amendment.

         2.       Section 1.1 in the License Agreement is hereby deleted in the
                  entirety and replaced by the following: The term "Subject
                  Technology" shall mean all technology, biological materials,
                  trade secrets, kits, compounds, know-how, methods, documents,
                  materials, tests, probes and all confidential information
                  related to the diagnosis of Charcot-Marie Tooth Disease which
                  was developed by Dr. James R. Lupski, Dr. Pragna Patel, Mr.
                  Montes de Oca-Luna and Ms. Saucedo Cardenas in laboratories at
                  BAYLOR. The Subject Technology shall also include United
                  States Patent Application Serial No. 07/711,615 filed June 6,
                  1991, entitled "Molecular Diagnosis of Charcot-Marie Tooth
                  Disease" and United States continuation-in-part application
                  #2, Serial No. 08/129,902, together with all valid patents or
                  patent applications, reexaminations, reissues, renewals,
                  extensions, divisions thereof (the "Licensed Patents"). The
                  continuation-in-part application #1 of United States Serial
                  No. 07/711, 615 is specifically excluded from the term
                  "Subject Technology."

         3.       Section 6.1 in the License Agreement is hereby deleted in the
                  entirety and replaced by the following: BAYLOR shall continue,
                  at its expense, the efforts commenced prior to the Agreement
                  Date to obtain a United States patent on

<PAGE>

                  Serial No. 07/711,615 and all valid patents or patent
                  applications, reexaminations, reissues, renewals, extensions
                  and divisions thereof. GENICA shall be responsible for all
                  costs and expenses incurred after April 1, 1994 for CIP #2,
                  Serial No. 08/129,902 and all valid patents or patent
                  applications, reexaminations, reissues, renewals, extensions
                  and divisions thereof. The Parties shall utilize patent
                  attorneys or agents of BAYLOR's choice for the filing,
                  prosecution and issuance of the Licensed Patents. GENICA
                  expressly authorizes and directs BAYLOR to instruct such
                  counsel to invoice GENICA directly for all of the expenses and
                  fees related to CIP #2. BAYLOR shall instruct its counsel to
                  copy GENICA on all correspondence related to the Licensed
                  Patents. BAYLOR and its faculty members shall cooperate fully
                  in the preparation, filing and prosecution of all United
                  States and foreign patent applications filed pursuant to this
                  paragraph.

         4.       Except as amended hereby, the License Agreement shall be and
                  remain in full force and effect. This First Amendment shall be
                  effective as of the date first written above.

                  IN WITNESS WHEREOF, BAYLOR and GENICA have executed this
Amendment upon the dates set forth below.
<TABLE>
<CAPTION>
GENICA PHARMACEUTICALS                          BAYLOR COLLEGE OF MEDICINE
  CORPORATION
<S>                                             <C>
Name:    /s/ Robert E. Flaherty                           /s/ C.R. Richardson
         ------------------------------                   -------------------------------
         Robert E. Flaherty                     Name:     C.R. Richardson
Title:   President and CEO                      Title:    Vice President for Finance and
                                                          Administration

Date:    March 29, 1994                         Date:     April 8, 1994
</TABLE>

                                      -2-<PAGE>

                                                                 Exhibit 10.1(l)

                            PATENT LICENSE AGREEMENT

         This Patent License Agreement, effective the date last signed by the
parties (April 17, 1996) hereinafter referred to as the "Agreement," is by and
between:

         Washington University, located at One Brookings Drive, St. Louis,
Mssouri 63130, an educational institution and corporation of the State of
Missouri, hereinafter referred to as "WU".

and

         Athena Diagnostics, Inc., located at Four Biotech Park, 377 Plantation
Street, Worcester, MA 01605, a corporation of the Commonwealth of Massachusetts,
hereinafter referred to as "ATHENA."

         WU and ATHENA agree as follows:

1.       BACKGROUND

         1.01 In the course of conducting biomedical and behavioral research, WU
investigators made inventions that may have commercial applicability.

         1.02 By assignment of rights from a WU employee, WU owns intellectual
property rights claimed in any United States patent applications and patents
corresponding to the assigned inventions. WU also owns any tangible embodiments
of these inventions actually reduced to practice by WU.

         1.03 WU desires to transfer these inventions to the private sector
through commercialization licenses to facilitate the commercial development of
products and processes for public use and benefit.

         1.04 ATHENA desires to acquire commercialization rights to this
invention in order to develop processes, methods, or marketable products for
public use and benefit.

2.       DEFINITIONS

         2.01  "Licensed Patent Rights" means:

         (a) The U.S. patent and patent applications listed in Appendix A, and
all divisions and continuations of these applications, all patents issuing from
such applications, divisions, and continuations, and any reissues,
reexaminations, and extensions of all such patents;

* Material omitted and filed separately with the Securities and Exchange
Commission pursuant to request for confidential treatment under Rule 406.

<PAGE>
                                      -2-

         (b) to the extent that the following contain one or more claims
directed to the invention or inventions claimed in (a) above: (i)
continuations-in-part of (a) above; (ii) all divisions and continuations of
these continuations-in-part; (iii) all patents issuing from such
continuations-in-part, divisions, and continuations; and (iv) any reissues,
reexaminations, and extensions of all such patents;

         (c) Japanese counterpart foreign applications and patents to (a) and
(b) above.

         Licensed Patent Rights shall not include (b) br (c) above to the extent
that they contain one or more claims directed to new matter which is not the
subject matter of a claim in (a) above.

         2.02 "Licensed Product(s)" means tangible materials which, in the
course of manufacture, use, or sale, would, in the absence of this Agreement,
(a) infringe one or more claims of the Licensed Patent Rights that have not been
held invalid or unenforceable by an unappealed or unappealable judgment of a
court of competent jurisdiction or (b) contain or make use of Technical
Developments.

         2.03 "Licensed Process(es)" means processes which, in the course of
being practiced, would, in the absence of this Agreement, (a) infringe one or
more claims of the Licensed Patent Rights that have not been held invalid or
unenforceable by an unappealed or unappealable judgment of a court of competent
jurisdiction or (b) contain or make use of Technical Developments.

         2.04 "Technical Developments" means all physical embodiments of
Licensed Patent Rights including technical data, drawings, and research
information, including all progeny and derivative works thereof, developed by or
under the supervision of Dr. Alan Pestronk ("Dr. Pestronk").

         2.05 "Technical Information" means all ideas, know-how, research
information, methods, procedures or processes developed by or under the
supervision of Dr. Pestronk and owned by WU which is not in the public domain
and which contributes to the practice of the Licensed Patent Rights and the
marketing of Licensed Products.

         2.06  "Territory" means the United States and Japan.

         2.07 "Contract Year" means the one year period beginning with the
Effective Date of this Agreement and each one year period thereafter.

         2.08 "Net Sales" means the total actual gross receipts for sales of
Licensed Products or practice of Licensed Processes by or on behalf of ATHENA or
its sublicensees, and from leasing, renting, or otherwise making Licensed
Products available to others without sale or

<PAGE>

                                      -3-

other dispositions, whether invoiced or not, less returns and allowances
actually granted, freight out, taxes or excise duties imposed on the transaction
(if separately invoiced), and wholesaler and cash discounts in amounts customary
in the trade. No deductions shall be made for commissions paid to individuals,
whether they be with independent sales agencies or regularly employed by ATHENA,
or sublicensees, and on its payroll, or for the cost of collections.

         2.09 "First Commercial Sale" means the initial transfer by or on behalf
of ATHENA or its sublicensees of Licensed Products or the initial practice of a
Licensed Process by or on behalf of ATHENA or its sublicensees in exchange for
cash or some equivalent to which value can be assigned for the purpose of
determining Net Sales.

         2.10 "Government" means the government of the United States of
     America.

         2.11 "Field of Use" means the use of Licensed Products as research
reagents and human diagnostics.

3.       GRANT OF RIGHTS

         3.01 Subject to the terms and conditions of this Agreement, WU hereby
grants and ATHENA accepts, an exclusive license under the Licensed Patent Rights
in the Territory to make, use, and sell Licensed Products in the Field of Use
and to practice and have practiced any Licensed Processes in the Field of Use.

         3.02 Subject to the terms and conditions of this Agreement, WU hereby
grants and ATHENA accepts an exclusive license in the Territory to make, use and
sell Technical Developments in the Field of Use.

         3.03 Subject to the terms and conditions of this Agreement, WU hereby
grants and ATHENA accepts, subject to the terms and conditions of this
Agreement, an exclusive license in the Territory to make, use and sell Technical
Information in the Field of Use.

         3.04 This Agreement confers no license or rights by implication,
estoppel, or otherwise under any patent applications or patents of WU other than
Licensed Patent Rights regardless of whether such patents are dominant or
subordinate to Licensed Patent Rights.

         3.05 ATHENA hereby grants to WU a non-exclusive, paid-up license and
right to practice Licensed Patent Rights, Technical Developments and Technical
Information for clinical testing, not to exceed [ ]* sulfatide diagnostic tests
per year, and [ ]* GALOP diagnostic tests per year. WU may also use such tests
for internal research purposes.

         3.06 ATHENA further grants to WU a non-exclusive license and right to
use all information, data and reports developed by ATHENA or by third parties
acting on behalf of or

<PAGE>

                                      -4-

under authorization from ATHENA for internal research purposes, subject to
patient confidentiality. WU will not provide any such information, data or
reports to third parties.

         3.07 In addition to the reserved license of Section 3.06 above, WU
reserves the right to grant nonexclusive licenses to academic and other
non-profit research institutions to make and to use the inventions defined by
the Licensed Patent Rights solely for purposes of research involving the
inventions themselves, and not for purposes of clinical diagnosis or in lieu of
purchase if the inventions are avaable as commercial products for research
purposes. The purpose of this research license is to encourage basic research.

         3.08 ATHENA shall ensure that "Patent Pending" and/or the Licensed
Patent Rights number for issued patents appears on all Licensed Products or
their labels.

         3.09 For each year that ATHENA pays to WU the annual minimum royalty
required under Article 6, WU hereby grants to ATHENA a right of first refusal to
exclusively license new inventions by Dr. Pestronk, or WU employees under Dr.
Pestronk's supervision, in the field of autoantibodies in neurological
disorders. Such right of first refusal shall expire ninety (90) days after
ATHENA receives written disclosure of such new invention from WU.

         3.10 For each year that ATHENA pays to WU the annual minimum royalty
required under Article 6, Dr. Pestronk will provide up to eight (8) days of
advice and support to ATHENA for grand round talks, development of audio or
video tapes and other activities to be mutually agreed upon, in support of the
field of autoimmune peripheral neuropathies. Such support will be at no charge
for the first Contract Year, and thereafter, at a reasonable per diem rate to be
agreed upon, except reimbursement of out-of-pocket expenses, which shall be
reimbursed within thirty (30) days after receipt of invoices from Dr. Pestronk.

         3.11 ATHENA agrees to provide Dr. Pestronk with positive sera and
clinical information concerning each patient, subject to patient confidentiality
and the availability of such data to ATHENA.

4.       SUBLICENSING

         4.01 Upon written approval by WU, which approval will not be
unreasonably withheld, ATHENA may enter into sublicensing agreements under the
Licensed Patent Rights.

         4.02 ATHENA agrees that any sublicenses granted by it shall provide
that the obligations to WU of Sections 5.01, 5.02, 8.01, 10.01, 10.02, 12.04,
12.05 and 13.08 of this Agreement shall be binding upon the sublicensee as if it
were a party to this Agreement. ATHENA further agrees to attach copies of these
Sections to all sublicense agreements.

<PAGE>

                                      -5-

         4.03 Any sublicenses granted by ATHENA shall provide for the
termination of the sublicense, or the conversion to a license directly between
such sublicensees and WU, at the option of the sublicensee, upon termination of
this Agreement under Article 13. Such conversion is subject to WU approval and
contingent upon acceptance by the sublicensee of the remaining provisions of
this Agreement.

         4.04 ATHENA agrees to forward to WU a copy of each fully executed
sublicense agreement postmarked within sixty (60) days of the execution of such
agreement.

5.       RESERVED GOVERNNIENT RIGHTS

         5.01 Should the Government jointly fund research supporting the
development of Licensed Patent Righits or new inventions, WU shall reserve on
behalf of the Government an irrevocable, nonexclusive, nontransferable,
royalty-free license for the practice of Licensed Patent Rights throughout the
world by or on behalf of the Government and on behalf of any foreign government
or international organization pursuant to any existing or future treaty or
agreement to which the Government is a signatory.

         5.02 ATHENA agrees that License Products used or sold in the United
States embodying Licensed Patent Rights or products produced through use of
Licensed Processes developed with Government funding shall be manufactured
substantially in the United States, unless a written waiver is obtained in
advance from WU.

6.       ROYALTIES AND REIMBURSEMENT

         6.01 Within thirty (30) days after the Effective Date, ATHENA will pay
to WU a nonrefundable license issue fee of $[ ]*, which shall be creditable
against earned royalties during the first Contract Year.

         6.02 For the second and each subsequent Contract Year, ATHENA agrees to
pay to WU a nonrefundable annual minimum royalty of $[ ]* for each Contract Year
until separate patent claims under the Licensed Patent Rights for the detection
of each of the IgM and IgG antibodies for sulfatide issue in the United States.
Starting with the next Contract Year after such patent issues, then the
nonreftmdable, annual minimum royalty shall be $[ ]* per Contract Year. The
annual minimum royalty shall be fully creditable against earned royalties under
6.03(a) in the Contract Year so earned. No carry forward of annual minimum
royalty credits shall be allowed. The minimum annual royalty is due and payable
within thirty (30) days of the end of each Contact Year.

         6.03 ATHENA and its sublicensees agree to pay WU earned royalties as
follows:

<PAGE>

                                      -6-

         (a) With regard to tests for autoantibodies to sulfatide based on
analysis of IgM or IgG or their combination:

                  (i)   During the first Contract Year, an earned royalty of
         [ ]%* of Net Sales;

                  (ii)  Until the date of issuance of the separate patent(s)
         described in 6.02, an earned royalty of [ ]%* of Net Sales;

                  (iii) Following the issuance of the patent claims in (ii), an
         earned royalty of [ ]%* of annual Net Sales until such annual Net Sales
         reach $[ ]*;

                  (iv)  For annual Net Sales in excess of $1 million in (iii),
         an earned royalty of [ ]%* of annual Net Sales.

         (b)  with regard to the GALOP test, an earned royalty of [    ]%* of
Net Sales.

         6.04 No multiple royalties shall be payable because any Licensed
Products or Licensed Processes are covered by more than one of the Licensed
Patent Rights.

         6.05 To the extent commercially practicable, ATHENA shall invoice, list
and bill any Licensed Product and non-Licensed Product as a separate item on
invoices and reports to customers. In the event ATHENA offers a non-assay
service in combination with the offer of any Licensed Product ("Combination
Service"), then the Net Sales revenue, for the purposes of determining royalties
due WU, shall be determined by multiplying the Net Sales revenue of such
Combination Service by the fraction A/(A+B), where A is the Net Sales revenue of
the Licensed Product then charged by ATHENA for such Licensed Product, when
performed and billed separately and B is the Net Sales revenue for the
non-Licensed Product then charged by ATHENA for such non-Licensed Product, when
performed and billed separately.

7.       DOMESTIC AND FOREIGN PATENT FILING, PROSECUTION, AND MAINTENANCE

         7.01 WU agrees to take responsibility for, and to diligently pursue the
preparation, filing, prosecution, and maintenance of any and all patent
applications or patents included in the Licensed Patent Rights, including
without limitation, any applications under 7.04, and shall furnish copies of
relevant patent related documents to ATHENA. ATHENA shall have the right to
approve WU patent counsel, such approval not to be unreasonably withheld.

         7.02 Each party shall promptly inform the other as to all matters that
come to its attention that may affect the preparation, filing, prosecution, or
maintenance of the Licensed Patent Rights and permit each other to provide
comments and suggestions, as far in advance as is

<PAGE>

                                      -7-

practical with respect to the preparation, filing, and prosecution of Licensed
Patent Rights, which comments and suggestions shall be considered by the other
party.

         7.03 ATHENA agrees to reimburse WU, within thirty (30) days after
receipt of an invoice from WU, for the following reasonable patent expenses
incurred after the Effective Date:

         (a)  All maintenance costs and fees for issued U.S. Patent
No. 5,443,952;

         (b) Except for patent filing expenses as provided in Section 7.04, all
prosecution and maintenance costs of divisional patent applications and issued
patents for sulfatide IgG and IgM S/Ns TBD;

         (c) All filing, prosecution and maintenance fees for US and Japanese
patent applications and issued patents for the GALOP diagnostic test currently
contained in continuation in part patent application S/Ns 08/137,895 and
08/481,144.

         7.04 WU shall pay for the preparation and initial filing fees of
divisional applications for sulfatide IgG and IgM autoantibody diagnostic tests.

         7.05 With regard to the GALOP diagnostic test, ATHENA shall be entitled
to a credit of patent prosecution and maintenance expenses for patent
applications and issued patents against the earned royalties of 6.03(b) for all
patent filing and maintenance costs paid by ATHENA to WU, exceeding $[ ]*.

8.       RECORD KEEPING

         8.01 ATHENA agrees to keep accurate and correct records of Licensed
Products made, used, or sold and Licensed Processes practiced under this
Agreement appropriate to determine the amount of royalties due WU. Such records
shall be retained for at least five (5) years following a given reporting
period. They shall be available during normal business hours for inspection at
the expense of WU by an accountant or other designated auditor selected by WU
and reasonably approved by ATHENA for the sole purpose of verifying reports and
payments thereunder. The accountant or auditor shall only disclose to WU
information relating to the accuracy of reports and payments made under this
Agreement. If an inspection shows an underreporting or underpayment in excess of
[ ]%* for any Contract Year, then ATHENA shall reimburse WU for the cost of the
inspection at the time ATHENA pays the unreported royalties, including any late
charges as required by Section 9.07 of this Agreement. All payments required
under this Section shall be due within thirty (30) days after receipt by ATHENA
of a written invoice from WU.

<PAGE>

                                      -8-

9.       REPORTS ON PROGRESS, SALES, AND PAYMENTS

         9.01 Ninety (90) days after the Effective Date ATHENA will provide to
WU a written commercialization plan ("Commercial Development Plan") under which
                                      ---------------------------
ATHENA intends to bring the subject matter of the Licensed Patent Rights into
commercial use. The Commercial Development Plan will be incorporated by
reference into this Agreement.

         9.02 Until First Commercial Sale, ATHENA shall provide written annual
reports on its product development progress or efforts to commercialize each
diagnostic test under the Commercial Development Plan for IgG, IgM and GALOP
within sixty (60) days after the start of each Contract Year. These progress
reports shall include, but not be limited to: progress on research and
development, status of applications for regulatory approvals, manufacturing,
sublicensing., and marketing efforts during the preceding calendar year, as well
as plans for the present calendar year. If reported progress differs
substantially from that projected in the Commercial Development Plan, ATHENA
shall explain the reasons for such differences. ATHENA may propose amendments in
any such annual report to the Commercial Development Plan, acceptance of which
by WU may not unreasonably be denied.

         9.03 ATHENA shall report to WU the date of the First Commercial Sale in
each country in the Territory within thirty (30) days of such occurrence.

         9.04 ATHENA shall submit to WU a royalty report on a semi-annual basis,
within thirty (30) days after the close of each six (6) month Contract Year
period. This report shall set forth for the preceding six (6) months the amount
of the Licensed Products sold or Licensed Processes practiced by or on behalf of
ATHENA in each country within the Territory, the Net Sales, and a calculation of
royalties payable. With each such royalty report, ATHENA shall submit payment of
the earned royalties due. If no earned royalties are due to WU for any reporting
period, the written report shall so state. The royalty report shall be certified
as correct by an authorized officer of ATHENA.

         9.05 ATHENA agrees to forward semi-annually to WU a copy of such
reports received by ATHENA from its sublicensees during the preceding half-year
period as shall be pertinent to a royalty accounting to WU by ATHENA for
activities under the sublicense.

         9.06 Royalties due under Article 6 shall be paid in U.S. dollars. For
conversion of foreign currency to U.S. dollars, the conversion rate shall be the
rate quoted in the Wall Street Journal on the day that the payment is made. WU
                   -------------------
checks and bank drafts shall be drawn on United States banks and shall be
payable to WU. Any taxes or other expenses incurred in the transfer or
conversion to U.S. dollars shall be paid entirely by ATHENA. All royalty
payments due under this Agreement shall be mailed to the following address:
Washington University, One Brookings Drive, Campus Box 1054, St. Louis, Missouri
63130.

<PAGE>

                                      -9-

         9.07  Late charges will be applied to any overdue payments at a rate of
[           ]* as of the date such payment is due, plus [           ]%*, for the
period that payment is due until the time payment is actually received. The
payment of such late charges shall not prevent WU from exercising any other
rights it may have as a consequence of the lateness of any payment.

         9.08 During the term of the Agreement, and for a period of five (5)
years following the expiration or earlier termination hereof, each party shall
maintain in confidence all information of the other party (including royalty
reports, test results and samples) disclosed by the other party (the
"Confidential Information"), and shall not disclose or grant the use of the
 ------------------------
Confidential Information except on a need-to-know basis to those directors,
officers, affiliates, employees, or representatives, to the extent such
disclosure is reasonably necessary in connection with such party's activities as
expressly authorized by the Agreement, or unless expressly approved in advance
by the other party. Each party shall notify the other promptly upon discovery of
any unauthorized use or disclosure of the other party's Confidential
Information.

         9.09 The confidentiality obligations contained in Section 9.08 shall
not apply to the extent that (a) any receiving party (the "Recipient") is
                                                           ---------
required (i) to disclose information by Law, order or regulation of a
governmental agency or a court of competent jurisdiction, or (ii) to disclose
information to any governmental agency for purposes of obtaining approval to
test or market a Licensed Product, provided in either case that the Recipient
shall provide written notice thereof to the other party and sufficient
opportunity to object to any such disclosure or to request confidential
treatment thereof; or (b) the Recipient can demonstrate that (i) the disclosed
information was public knowledge at the time of such disclosure to the
Recipient, or thereafter became public knowledge, other than as a result of
actions of the Recipient in violation hereof; (ii) the disclosed information was
rightfully known by the Recipient (as shown by its written records) prior to the
date of disclosure to the Recipient by the other party hereunder; or (iii) the
disclosed information was disclosed to the Recipient on an unrestricted basis
from a source unrelated to any party to the Agreement and not under a duty of
confidentiality to the other party. Except as otherwise provided immediately
above, WU and ATHENA shall not disclose any terms or conditions of this
Agreement to any third party without the prior consent of the other party.

10.      PERFORMANCE

         10.01 ATHENA shall be diligent and shall use its reasonable efforts to
introduce the Licensed Products into the commercial market or apply the Licensed
Processes to commercial use as listed herein. "Reasonable efforts" for the
purpose of this provision shall include, but not be limited to, substantial
adherence to the Commercial Development Plan. The efforts of a sublicensee shall
be considered the efforts of ATHENA. As part of the Commercial Development Plan,
ATHENA hereby agrees to cornmercially introduce the GALOP diagnostic test within
one (1) year after the Effective Date.

<PAGE>

                                      -10-

         10.02 Upon the First Commercial Sale, until the expiration of this
Agreement, ATHENA shall use its reasonable efforts to keep Licensed Products and
Licensed Processes reasonably accessible to the public.

         10.03 ATHENA shall be considered diligent in its sales of Licensed
Products, sulfatide IgG and IgK, provided ATHENA pays its annual minimum royalty
due in any Contract Year. For the GALOP diagnostic test, ATHENA shall be
considered diligent provided that the GALOP diagnostic test is made reasonably
available in the Territory.

11.      INFRINGEMENT AND PATENT ENFORCEMENT

         11.01 If ATHENA or WU has actual notice of infringement or possible
infringement of the Licensed Patent Rights, the parties shall notify each other
and confer to determine in good faith an appropriate course of action to enforce
the Licensed Patent Rights or otherwise abate the infringement thereof.

         11.02 ATHENA, at its sole expense and in its sole discretion, shall
have the right to (i) determine and take the appropriate course of action to
enforce the Licensed Patent Rights or otherwise abate the infringement thereof,
(ii) take or refrain from taking appropriate action to enforce the Licensed
Patent Rights, (iii) initiate and control any litigation or other enforcement
action, including without limitation any declaratory relief action asserting the
invalidity or noninfringement of any of the Licensed Patent Rights (in its own
name or, if required by applicable law, in the came of WU) and (iv) enter into,
or permit, the settlement of any such litigation or other enforcement action
regarding the Licensed Patent Rights, and shall consider, in good faith, the
interest of WU in so doing. At any time after receipt of notice, of ATHENA's
intent to file or respond to any such suit under this Section, WU shall have the
right to join such suit, and shall pay its own fees and costs if it chooses to
do so. WU shall join as a necessary party in any such suit if required to do so
by applicable law. If WU is joined as a necessary party without its consent,
ATHENA will pay reasonable fees and costs actually incurred by WU upon the
presentation of detailed invoices. ATHENA will keep WU reasonably apprised of
the status and progress of any such litigation.

         11.03 If ATHENA does not, within one hundred and twenty (120) days of
receipt of written request to do so from WU, abate the infringement or file suit
to enforce the Licensed Patent Rights against at least one infringing party, WU
shall have the right to take or refrain from taking appropriate action to
enforce the Licensed Patent Rights, to initiate and control any litigation or
other enforcement action and enter into, or permit, the settlement of any such
litigation or other enforcement action regarding the Licensed Patent Rights, and
shall consider, in good faith, the interests of ATHENA in so doing. WU will keep
ATHENA reasonably apprised of the status and progress of any such litigation. At
any time after receipt of notice of WU's intent to file any such suit under this
Section, ATHENA shall have the right to join in such suit and shall pay its own
fees and costs if it chooses to do so.

<PAGE>

                                      -11-

         11.04 ATHENA shall have the right to credit all actual, reasonable,
external expenses (including reasonable attorneys fees and costs), incurred by
ATHENA and its affiliates in the planning, filing and prosecution or defense of
any suit or other enforcement action under this Section, against any royalties
owning to WU pursuant to Section 6.03(a) or 6.03(b), as the case may be, until
such time as ATHENA has taken a credit equal to the aggregate amount of such
expenses, except that such credit may not exceed in any Contract Year, [ ]%* of
the royalties owned by ATHENA for that Contract Year, and in any event may not
reduce the royalties below the minimum royalties provided in Section 6.02.
Expenses not so credited may be carried over and credited in subsequent Contract
Years on the same basis.

         11.05 All amounts recovered upon the final judgment or settlement of
any such suit or other enforcement action under this Section regarding the
Licensed Patent Rights shall be shared as follows: first, to WU and ATHENA, pro
rata, for reimbursement of expenses actually incurred by each of them in
accordance with this Section in the infringement proceeding to which the
settlement or recovery relates (to the extent not already recovered by ATHENA by
credits against royalties, as provided in the above section); and thereafter,
equally between WU and ATHENA.

         11.06 WU and ATHENA shall fully cooperate with each other in the
planning, filing and prosecution of any suit or other enforcement action under
this Section and execute all such documents as may be reasonably necessary in
connection therewith.

12.      NEGATION OF WARRANTIES, INDEMNIFICATION AND INSURANCE

         12.01 WU offers no warranties other than those specified in Article 1.

         12.02 WU does not warrant the validity of the Licensed Patent Rights
and makes no representations whatsoever with regard to the scope of the Licensed
Patent Rights, or that the Licensed Patent Rights may be exploited without
infringing other patents or other intellectual property rights of third parties.
WU does not represent that it will commence legal actions against third parties
infringing the Licensed Patent Rights.

         12.03 WU MAKES NO WARRANTIES, EXPRESSED OR IMPLIED, OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS
OF THE LICENSED PATENT RIGHTS.

         12.04 ATHENA shall indemnify, defend and hold harmless WU, their
trustees, officers and employees, against any liability, damage, loss or expense
incurred by or imposed upon WU in connection with any claims, suits, actions,
demands or judgments arising out of (i) the design, production, manufacture,
sale, use in commerce, lease, barter, or promotion by ATHENA or by ATHENA
subsidiaries or agents of ATHENA, (ii) any Licensed Product, process or service
relating to or developed pursuant to this Agreement by ATHENA; or (iii)

<PAGE>

                                      -12-

any other activities to be carried out pursuant to this Agreement including the
assertion of Licensed Patent Rights against third parties, except to the extent
of any gross negligence or willful misconduct of WU, its officers, employees or
representatives.

         12.05 Throughout the term of the Agreement, ATHENA shall, at its sole
cost and expense, procure and maintain comprehensive general liability insurance
with product liability coverage in an amount not less than $[ ]* per incident
and $[ ]* annual aggegate, with such excess coverage as ATHENA may deem
reasonable and appropriate. Within ten (10) days of the date of this Agreement,
ATHENA will provide WU with a certificate of insurance in the name of WU. The
minimum amounts of insurance coverage stated above shall not be construed to
create a limit of ATHENA's liability with respect to any indemnification
obligations under this Agreement. ATHENA will give written notice to WU in the
event of cancellation or termination of such liability or excess coverage. All
carriers of such insurance shall be of nationally recognized standing, and shall
maintain ratings no less than those currently in effect for ATHENA's current
insurance carrier, unless reasonably acceptable to WU. If ATHENA elects to
self-insure, all or part of the limits described above (excluding deductibles or
retentions of less than $[ ]* annual aggregate), such self-insurance program
must be reasonably acceptable to WU.

13.      TERM, TERMINATION, AND MODIFICATION OF RIGHTS

         13.01 This Agreement is effective when signed by all parties and shall
extend to the expiration of the last to expire of the Licensed Patent Rights
unless sooner terminated as provided in this Article 13.

         13.02 In the event that ATHENA is in default in the performance of any
material obligations under this Agreement, and if the default has not been
remedied within ninety (90) days after the date of notice in writing of such
default, WU may terminate this Agreement by written notice.

         13.03 At least thirty (30) days prior to filing a petition in
bankruptcy, ATHENA must inform WU in writing of its intention to file the
petition in bankruptcy or of a third party's intention to file an involuntary
petition in bankruptcy.

         13.04 In the event that ATHENA becomes insolvent, files a petition in
bankruiptcy, has such a petition filed against it, determines to file a petition
in bankruptcy, or receives notice of a third party's intention to file an
involuntary petition in bankruptcy, ATHENA shall immediately notify WU in
writing. Furthermore, WU shall have the right to terminate this Agreement by
giving ATHENA written notice. Termination of this Agreement is effective upon
ATHENA's receipt of the written notice.

<PAGE>

                                      -13-

         13.05 ATHENA shall have a unilateral right to terminate this Agreement
and/or any licenses in any country by giving WU sixty (60) days' written notice
to that effect.

         13.06 WU shall specifically have the right to terminate or render
non-exclusive, at its option, this Agreement, if WU determines that ATHENA: (a)
is not executing the Commercial Development Plan submitted with its request for
a license and ATHENA cannot otherwise demonstrate to WU's satisfaction that
ATHENA has taken, or can be expected to take within a reasonable time, effective
steps to achieve practical application of the Licensed Products or Licensed
Processes; (b) has not been reasonably diligent in its pursuit of the milestones
in the Product Plan; (c) has willfully made a false statement of, or willfully
omitted, a material fact in the license application or in any report required by
the license agreement; (d) has committed a substantial breach of a covenant or
agreement contained in the license; (e) is not keeping Licensed Products or
Licensed Processes reasonably available to the public after commercial use
commences; or, (f) cannot reasonably justify a failure to comply with the
domestic production requirement of Section 5.02 unless waived. In making this
determination, WU will take into account the normal course of such commercial
development programs conducted with sound and reasonable business practices and
judgment and the annual reports submitted by ATHENA under Sections 9.02 and
9.04. Prior to invoking this right, WU shall give written notice to ATHENA
providing ATHENA specific notice of, and a ninety (90) day opportunity to
respond to, WU's concerns as to the previous items (a) through (f). If ATHENA
fails to reasonably alleviate WU's concerns as to the previous items (a) through
(f) or fails to initiate corrective action to WU's reasonable satisfaction, WU
may terminate this Agreement.

         13.07 When the public health and safety so require, and after written
notice to ATHENA providing ATHENA a sixty (60) day opportunity to respond, WU
shall have the right to require ATHENA to grant sublicenses to responsible
applicants, on reasonable terms, in any Field of Use under the Licensed Patent
Rights, unless ATHENA can reasonably demonstrate that the granting of the
sublicense would not materially increase the availability to the public of the
subject matter of the Licensed Patent Rights. WU will not require the granting
of a sublicense unless the responsible applicant has first negotiated in good
faith with ATHENA.

         13.08 Within ninety (90) days of termination of this Agreement under
this Article 13 or expiration under Section 13.01, a final report shall be
submitted by ATHENA. Any royalty payments, including those related to patent
expense, due to WU shall become immediately due and payable upon termination or
expiration. If terminated under this Article 13, sublicensees may elect to
convert their sublicenses to direct licenses with WU pursuant to Section 4.03.

         13.09 Notwithstanding anything in this Agreement to the contrary, WU's
remedies under Section 13.06 must be exercised solely and separately, as between
IgG/IgM sulfatide

<PAGE>

                                      -14-

antibody tests, on the one hand, and GALOP, on the other, according to the
actual alleged breach or default.

14.      GENERAL PROVISIONS

         14.01 Neither Party may waive or release any of its rights or interests
in this Agreement except in writing. The failure of WU to assert a right
hereunder or to insist upon compliance with any term or condition of this
Agreement shall not constitute a waiver of that right by WU or excuse a similar
subsequent failure to perform any such term or condition by ATHENA.

         14.02 This Agreement constitutes the entire agreement between the
Parties relating to the subject matter of the Licensed Patent Rights, and all
prior negotiations, representations, agreements, and understandings are merged
into, extinguished by, and completely expressed by this Agreement.

         14.03 The provisions of this Agreement are severable, and in the event
that any provision of this Agreement shall be determined to be invalid or
unenforceable under any controlling body of law, such determination shall not in
any way affect the validity or enforceability of the remaining provisions of
this Agreement.

         14.04 If either Party desires a modification to this Agreement, the
Parties shall, upon reasonable notice of the proposed modification by the Party
desiring the change, confer in good faith to determine the desirability of such
modification. No modification will be effective until a written amendment is
signed by the signatories to this Agreement or their designees.

         14.05 The construction, validity, performance, and effect of this
Agreement shall be governed by Federal law as applied by the Federal courts in
the State of Missouri.

         14.06 All notices required or permitted by this Agreement shall be
given by prepaid, first class, registered or certified mail properly addressed
to the other Party at the address designated on the following Signature Page, or
to such other address as may be designated in writing by such other Party, and
shall be effective as of the date of the postmark of such notice.

         14.07 This Agreement shall not be assigned by ATHENA except (a) with
the prior written consent of WU, such consent to be reasonably given; or (b) as
part of a sale or transfer of substantially the entire business of ATHENA
relating to operations which concern this Agreement. ATHENA shall notify WU
within ten (10) days of any assignment of this Agreement by ATHENA.

<PAGE>

                                      -15-

         14.08 ATHENA agrees in its use of any WU-supplied materials to comply
with all applicable statutes, regulations, and guidelines, including Public
Health Service and National institutes of Health regulations and guidelines.
ATHENA agrees not to use the materials for research involving human subjects or
clinical trials of the United States without notifying WU, in writing, of such
research or trials and complying with the applicable regulations of the appro
priate Government authorities. Written notification to WU of research involving
human subjects or clinical trials of the United States shall be given no later
than sixty (60) days prior to commencement of such research or trials.

         14.09 ATHENA acknowledges that it is subject to and agrees to abide by
the United States laws and regulations (including the Export Administration Act
of 1979 and Arms Export Control Act) controlling the export of technical data,
computer software, laboratory prototypes, biological material, and other
commodities. The transfer of such items may require a license from the cognizant
agency of the U.S. Government or written assurances by ATHENA that it shall not
export such items to certain foreign countries without prior approval of such
agency. WU neither represents that a license is or is not required or that, if
required, it shall be issued.

         14.10 All Licensed Products manufactured in, shipped to, or sold in
other countries shall be marked in such a manner as to preserve WU patent rights
in such countries.

         14.11 By entering into this Agreement, WU does not directly or
indirectly endorse any product or service provided, or to be provided, by ATHENA
whether directly or indirectly related to this Agreement. ATHENA shall not state
or imply that this Agreement is an endorsement by WU or its employees.
Additionally, ATHENA shall not use the names of WU or its employees in any
advertising, promotional, or sales literature without the prior written consent
of WU.

         14.12 The Parties agree to attempt to settle amicably any controversy
or claim arising under this Agreement or a breach of this Agreement. Any dispute
or claim arising out of this Agreement that cannot be settled by and between the
Parties to their mutual satisfaction within a reasonable period of time shall be
submitted to non-binding arbitration in St. Louis, Missouri under the Commercial
Arbitration Rules of the American Arbitration Association by one arbitrator
appointed in accordance with said Rules. The arbitrator shall apply Missouri law
to the merits of any dispute or claim, without reference to rules of conflicts
of law. Judgment on the award rendered by the arbitrator may be entered in any
court having jurisdiction thereof. Either party may file an action in a court of
competent jurisdiction for a de novo hearing regarding such arbitrated disputes.
The parties agree that decisions of the arbitrator are admissible and discovery
conducted during arbitration may be used in such action. Should the court
substantially uphold the findings of the arbitrator, the party seeking the de
novo hearing shall pay all parties costs involved including reasonable
attorney's fees.

<PAGE>

                                      -16-

         14.13 Sections 4.03, 8.01, 9.06, 9.07, 12.01-12.05, and 14.12 of this
Agreement shall survive termination of this Agreement.

                             FOR WASHINGTON UNIVERSITY:

                             By: /s/   H.S. Leahey
                                ---------------------------------------------
                                Name:  H.S. Leahey
                                Title: Director, Technology Management

                             FOR ATHENA DIAGNOSTICS, INC.

                             By: /s/   Robert Flaherty
                                ---------------------------------------------
                                Name: Robert Flaherty
                                Title: President

<PAGE>

                                   APPENDIX A

                             LICENSED PATENT RIGHTS

ISSUED UNITED STATES PATENTS
US Patent No. 5,443,952

PENDING UNITED STATES PATENTS

Patent Application S/N 07/743,005 (abandoned)

Patent Application S/N 07/925,926 (abandoned) - Continuation of 07/743,005

Patent Application S/N 08/137,895 (pending) - Continuation in Part of 07/925,926

Patent Application S/N 08/481,144 (pending) - Continuation in Part of 08/137,895

Divisional Patent Application, S/N TBD - IgG and IgM independent claims.

<PAGE>

                                      -2-

                   FIRST AMENDMENT TO PATENT LICENSE AGREEMENT

         THIS FIRST AMENDMENT TO PATENT LICENSE AGREEMENT is effective December
17, 1997, by and between Washington University ("WU"), an educational
institution and corporation of the State of Missouri, with an address of One
Brookings Drive, St. Louis, Missouri 63130, and Athena Diagnostics, Inc., a
Massachusetts corporation, with an address of Four Biotech Park, 377 Plantation
Street, Worcester, Massachusetts 01605 ("ATHENA").

         WHEREAS, WU and ATHENA entered into a Patent License Agreement
effective April 17, 1996 (the "License Agreement");
                               -----------------

         WHEREAS, WU and ATHENA desire to extend the terms of the License
Agreement, in the manner hereinafter set forth;

         NOW, THEREFORE, in consideration of the mutual covenants contained
herein and for good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the parties hereby agree as follows:

         The Patent License Agreement. Except as specifically set forth herein
         ----------------------------
in this First Amendment to Patent License Agreement (hereinafter "First
                                                                  -----
Amendment"), the parties hereby ratify and confirm each and every term,
---------
representation, warranty, covenant and condition of the License Agreement which
shall remain in full force and effect; provided, however, that in the event of
                                       --------  -------
any conflict between the License Agreement and this First Amendment, this First
Amendment shall govern and control.

         Background. Paragraphs 1.06 and 1.07 shall be added to the License
         ----------
Agreement as follows:

         1.06  WU is the owner of the GALOP mark (the "Mark") in connection with
         the Licensed Products and Licensed Process (defined below), including
         diagnostic services incorporating an assay for Gait Disorder
         Auto-Antibody Late Onset Polyneuropathy.

         1.07  WU desires to grant and ATHENA desires to acquire a license to
         use the Mark in connection with diagnostic services incorporating the
         assay for Gait Disorder Auto-Antibody Late Onset Polyneuropathy (the
         "Licensed Services") under the terms and conditions provided herein.

         Trademark Filing, Prosecution and Maintenance.  Section 7a shall be
         ---------------------------------------------
added to the License Agreement as follows:

         7a.  TRADEMARK FILING, PROSECUTION AND MAINTENANCE.

<PAGE>
                                      -3-

         7a.01 Subject to the terms and conditions of this Agreement, WU hereby
         grants and ATHENA accepts, an exclusive, paid-up, license to use the
         Mark in the Territory in connection with the Licensed Services, except
         that WU reserves the right to use the Mark in connection with ATHENA's
         grant back of rights under Section 3.05 of the License Agreement.
         ATHENA acknowledges that its use of the Mark will not create in it any
         right, title or interest in or to the Mark other than as set forth
         herein. ATHENA agrees to use the Mark in a manner that creates a
         separate and distinct impression from any other trademark or service
         mark that may be used by ATHENA in advertising or promotional
         materials.

         7a.02 ATHENA agrees, at its expense, on WU's behalf and in WU's name,
         to take responsibility for, and to diligently pursue the preparation,
         filing, prosecution and maintenance of U.S. federal trademark
         applications with respect to the Mark. In addition, ATHENA may, in its
         sole discretion, pursue the preparation, filing, prosecution and
         maintenance of trademark applications with respect to the Mark in other
         jurisdictions within the Territory. During the term of this Agreement
         and any subsequent renewal thereof, ATHENA further agrees to take all
         steps required to maintain any registrations that result from said
         applications. At ATHENA's request, WU agrees to do all lawful acts
         which may be required for filing, prosecuting and maintaining said
         applications and the registrations issuing therefrom. ATHENA shall
         furnish copies of relevant trademark-related documents to WU. WU will
         retain ownership of the Mark, and any applications or registrations
         therefor.

         7.a03 Given the parties' mutual interest in the Mark, the parties agree
         to promptly inform each other as to all matters that may have a
         material impact on the Mark, or any applications or registrations
         therefor. Communications in this regard will be made as far in advance
         as is practical, allowing each party the opportunity to comment and/or
         make suggestions with respect thereto. It is understood, however, that
         WU, as owner of the Mark, has the right to make all final decisions
         concerning the Mark and any corresponding applications or registrations
         therefor.

         7.a04 ATHENA shall use the Mark in connection with the Licensed
         Services in accordance with the guidelines and directions furnished by
         WU, as set forth in the License Agreement and the patents and patent
         applications attached thereto as Appendix A. ATHENA will permit WU, or
         its designated representative, to inspect ATHENA's facility or
         facilities at all reasonable times, for the purpose of ascertaining or
         determining the quality of services provided in con-

<PAGE>

                                      -4-

         nection with the Mark. WU shall be the sole judge of whether or not
         ATHENA has met or is meeting the standards of quality so established.

         7.a05 The provisions of Sections 4.01 to 4.04 of the License Agreement
         shall apply with equal force and effect to the rights granted herein to
         the Mark. In addition, ATHENA agrees that any sublicenses granted by it
         shall provide that Section 7.a04 shall be binding upon the sublicensee
         as if it were a party to the Licnese Agreement. ATHENA agrees to attach
         a copy of that Section to all sublicense agreements.

         7.a06 The provisions of Sections 11.01 to 11.06 of the License
         Agreement shall apply with equal force and effect to the rights granted
         herein to the Mark.

         7.a07 The license granted in this Section 7a to use the Mark in
         connection with the Licensed Services shall terminate upon termination
         or expiration of the License Agreement, provided, however, that ATHENA
                                                 --------  -------
         may use the Mark for a period of six (6) months for ATHENA's
         stock-on-hand promotional literature, stationery, packaging, and other
         printed or written materials. However, if any such materials remain in
         ATHENA's stock-on-hand after the six months, ATHENA agrees to destroy
         all such materials, other than archival copies. Upon termination of the
         license granted in this Section 7a, all trademark rights granted herein
         shall immediately revert to WU, and any and all rights of ATHENA in the
         Mark shall terminate. ATHENA shall no longer use or have the right to
         use the mark, any variation or deviation thereof, or any work, mark, or
         trade name confusingly similar thereto.

         7.a08 WU hereby grants ATHENA a first option to negotiate in good faith
         with ATHENA for an exclusive license to the MARK after expiration of
         the last to expire Licensed Patent Rights and the right to use the Mark
         for no more than six (6) months during the negotiations under the
         option. If no license to the Mark is granted or taken under the option,
         then ATHENA may make reference in its promotional materials, and its
         other written and printed materials to the Mark for a period of one (1)
         year after expiration of the last to expire Licensed Patent Rigths to
         advise its customers and prospective customers that the services
         incorporating an assay for Gait Disorder Auto-Antibody Late Onset
         Polyneuropathy was formerly known as the GALOP service.

         This document sets forth the entire agreement between the parties as to
the subject matter of the First Amendment and supersedes any prior written or
oral or contemporaneous oral agreement with respect thereto.

<PAGE>
                                      -5-

         IN WITNESS WHEREOF, WU and ATHENA hereby execute this First Amendment
to Patent License Agreement.

ATHENA DIAGNOSTICS, INC.                   WASHINGTON UNIVERSITY

By:/s/  Robert Flaherty                   By:/s/  Theodore J. Cicero
   --------------------------------          -----------------------------------
Name:   Robert Flaherty                   Name:   Theodore J. Cicero, Ph.D.
Title:  President                         Title:  Vice Chancellor for Research

                                                                        12/17/97

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}]]